X P Min1, T Y Zhu1, J Han1, Y Li1, X Meng2. 1. Department of Cardiac Surgery, Atrial Fibrillation Center, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, 100029, Chaoyang District, Beijing, China. 2. Department of Cardiac Surgery, Atrial Fibrillation Center, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, 100029, Chaoyang District, Beijing, China. mxheart09@sina.com.
Abstract
BACKGROUND: Left atrial appendage (LAA) obliteration is a proven stroke-preventive measure for patients with nonvalvular atrial fibrillation (AF). However, the efficacy of LAA obliteration for patients with AF after bioprosthetic mitral valve replacement (MVR) remains unclear. AIM: This study aimed to estimate the efficacy of LAA obliteration in preventing embolism and to investigate the predictors of thromboembolism after bioprosthetic MVR. METHODS: We retrospectively studied 173 AF subjects with bioprosthetic MVR; among them, 81 subjects underwent LAA obliteration using an endocardial running suture method. The main outcome measure was the occurrence of thrombosis events (TEs). The mean follow-up time was 40 ± 17 months. RESULTS: AF rhythm was observed in 136 patients postoperatively. The incidence rate of TEs was 13.97 % for postoperative AF subjects; a dilated left atrium (LA; > 49.5 mm) was identified as an independent risk factor of TEs (OR = 10.619, 95 % CI = 2.754-40.94, p = 0.001). For postoperative AF patients with or without LAA, the incidence rate of TEs was 15.8 % (9/57) and 12.7 % (10/79; p = 0.603), respectively. The incidence rate of TEs was 2.7 % (1/36) and 4.2 % (2/48) for the subgroup patients with a left atrial diameter of < 49.5 mm, and 38.1 % (8/21) and 25.8 % (8/31) for those with a left atrial diameter of > 49.5 mm (p = 0.346). CONCLUSION: Surgical LAA obliteration in patients with valvular AF undergoing bioprosthetic MVR did not reduce TEs, even when the CHA2DS2-VASc score (a score for estimating the risk of stroke in AF) was ≥ 2 points.
BACKGROUND: Left atrial appendage (LAA) obliteration is a proven stroke-preventive measure for patients with nonvalvular atrial fibrillation (AF). However, the efficacy of LAA obliteration for patients with AF after bioprosthetic mitral valve replacement (MVR) remains unclear. AIM: This study aimed to estimate the efficacy of LAA obliteration in preventing embolism and to investigate the predictors of thromboembolism after bioprosthetic MVR. METHODS: We retrospectively studied 173 AF subjects with bioprosthetic MVR; among them, 81 subjects underwent LAA obliteration using an endocardial running suture method. The main outcome measure was the occurrence of thrombosis events (TEs). The mean follow-up time was 40 ± 17 months. RESULTS:AF rhythm was observed in 136 patients postoperatively. The incidence rate of TEs was 13.97 % for postoperative AF subjects; a dilated left atrium (LA; > 49.5 mm) was identified as an independent risk factor of TEs (OR = 10.619, 95 % CI = 2.754-40.94, p = 0.001). For postoperative AFpatients with or without LAA, the incidence rate of TEs was 15.8 % (9/57) and 12.7 % (10/79; p = 0.603), respectively. The incidence rate of TEs was 2.7 % (1/36) and 4.2 % (2/48) for the subgroup patients with a left atrial diameter of < 49.5 mm, and 38.1 % (8/21) and 25.8 % (8/31) for those with a left atrial diameter of > 49.5 mm (p = 0.346). CONCLUSION: Surgical LAA obliteration in patients with valvular AF undergoing bioprosthetic MVR did not reduce TEs, even when the CHA2DS2-VASc score (a score for estimating the risk of stroke in AF) was ≥ 2 points.
Entities:
Keywords:
Atrial fibrillation; Bioprosthetic mitral valve replacement; Left atrial appendage; Left atrial dimension; Thrombosis events
Authors: E S Katz; T Tsiamtsiouris; R M Applebaum; A Schwartzbard; P A Tunick; I Kronzon Journal: J Am Coll Cardiol Date: 2000-08 Impact factor: 24.094
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2014-03-28 Impact factor: 24.094
Authors: Marcos Daccarett; Troy J Badger; Nazem Akoum; Nathan S Burgon; Christian Mahnkopf; Gaston Vergara; Eugene Kholmovski; Christopher J McGann; Dennis Parker; Johannes Brachmann; Rob S Macleod; Nassir F Marrouche Journal: J Am Coll Cardiol Date: 2011-02-15 Impact factor: 24.094
Authors: L Gonzalez-Lavin; A P Tandon; S Chi; T C Blair; P M McFadden; B Lewis; G Daughters; M Ionescu Journal: J Thorac Cardiovasc Surg Date: 1984-03 Impact factor: 5.209